Pharming Group (XAMS:PHARM) Cyclically Adjusted Revenue per Share: €0.31 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XAMS:PHARM Pharming Group XAMS:PHARM
80 GF Score
Price €1.16
GF Value €1.28
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Cyclically Adjusted Revenue per Share?

Pharming Group XAMS:PHARM -0.98% 80 Cyclically Adjusted Revenue per Share is €0.31 as of Mar. 2026. GuruFocus rates XAMS:PHARM with a GF Score™ of 80/100 and a GF Value™ of €1.28 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharming Group's adjusted revenue per share for the three months ended in Mar. 2026 was €0.084. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharming Group's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharming Group was 23.30% per year. The lowest was 17.30% per year. And the median was 18.60% per year.

As of today (2026-07-17), Pharming Group's current stock price is €1.1585. Pharming Group's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.31. Pharming Group's Cyclically Adjusted PS Ratio of today is 3.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharming Group was 22.01. The lowest was 2.65. And the median was 6.15.


Pharming Group  (XAMS:PHARM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharming Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.1585/0.31
=3.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharming Group was 22.01. The lowest was 2.65. And the median was 6.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharming Group Cyclically Adjusted Revenue per Share Related Terms


Pharming Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharming Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Cyclically Adjusted Revenue per Share Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.18 0.21 0.25 0.30

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.27 0.29 0.30 0.31

XAMS:PHARM vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted PS Ratio falls into.


XAMS:PHARM
80GF Score
Pharming Group XAMS:PHARM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharming Group's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.084/136.9100*136.9100
=0.084

Current CPI (Mar. 2026) = 136.9100.

Pharming Group Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.007 100.260 0.010
201609 0.008 100.570 0.011
201612 0.014 100.710 0.019
201703 0.032 101.440 0.043
201706 0.034 101.370 0.046
201709 0.051 102.030 0.068
201712 0.060 101.970 0.081
201803 0.043 102.470 0.057
201806 0.043 103.100 0.057
201809 0.057 103.950 0.075
201812 0.056 103.970 0.074
201903 0.052 105.370 0.068
201906 0.066 105.840 0.085
201909 0.063 106.700 0.081
201912 0.071 106.800 0.091
202003 0.064 106.850 0.082
202006 0.059 107.510 0.075
202009 0.067 107.880 0.085
202012 0.071 107.850 0.090
202103 0.056 108.870 0.070
202106 0.047 109.670 0.059
202109 0.056 110.790 0.069
202112 0.070 114.010 0.084
202203 0.061 119.460 0.070
202206 0.064 119.050 0.074
202209 0.080 126.890 0.086
202212 0.073 124.940 0.080
202303 0.062 124.720 0.068
202306 0.063 125.830 0.069
202309 0.090 127.160 0.097
202312 0.085 126.450 0.092
202403 0.078 128.580 0.083
202406 0.075 129.910 0.079
202409 0.130 131.610 0.135
202412 0.122 131.630 0.127
202503 0.109 133.330 0.112
202506 0.099 133.960 0.101
202509 0.119 135.920 0.120
202512 0.120 135.270 0.121
202603 0.084 136.910 0.084

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.31 mean?
Pharming Group (XAMS:PHARM) has a Cyclically Adjusted Revenue per Share of €0.31 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharming Group and its competitors.
Is Pharming Group's Cyclically Adjusted Revenue per Share too high?
Pharming Group's current Cyclically Adjusted Revenue per Share is €0.31. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharming Group's Cyclically Adjusted Revenue per Share of €0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharming Group and its competitors. Pharming Group's current Cyclically Adjusted Revenue per Share is €0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (XAMS:PHARM) is currently considered Fairly Valued. The stock's GF Value™ is €1.28, compared to a current price of €1.16 — trading 9.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.31. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharming Group (XAMS:PHARM), the current Cyclically Adjusted Revenue per Share is €0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (XAMS:PHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.16 is trading 9.5% below its estimated GF Value™ of €1.28. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for XAMS:PHARM:

  • Cyclically Adjusted Revenue per Share: €0.31
  • GF Value™: €1.28 vs. price of €1.16 (9.5% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for XAMS:PHARM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.16
Price
€1.28
GF Value